Our primary focus lies in the development of non-opioid products for meeting the needs of under served patients with back pain. We believe we have the technology to improve products' efficacy and safety and make a critical difference in the treatment of back pain patients.
Semnur Pharmaceutials, Inc. is currently advancing a portfolio of novel injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapies. Our lead program, SP-102 is a novel gel formulation of well known steroid administered epidurally for patients with moderate to severe chronic back pain.
SP-102 has completed a successful Phase 1/2 trial in lumbar radicular pain patients and we anticipate initiation of a pivotal multi-center U.S. Phase 3 trial this year.
Semnur Pharmaceuticals, Inc. is being acquired by Scintilla Pharmaceuticals, Inc.